Scholar Rock Holding (SRRK) Return on Capital Employed (2018 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Return on Capital Employed of 99.87% for Q1 2026, down 3280.0% year-over-year from 3.14% in Q1 2025, and up 8.46% quarter-over-quarter from 109.1% in Q4 2025.
Scholar Rock Holding (SRRK) Return on Capital Employed (2018 - 2026) Analysis & Trends
Scholar Rock Holding's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 99.87% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3280.0% year-over-year to 99.87%; the TTM figure through Mar 2026 stood at 99.87% (down 3280.0% YoY), while the FY2025 annual figure was 100.12%, down 2728.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 99.87%, up from 109.1% in the prior quarter.
- The five-year high for Return on Capital Employed was 34.62% in Q3 2022, with the low at 141.01% in Q3 2024.
- The 5-year median for Return on Capital Employed is 69.04% (2023), against an average of 76.71%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 7311 bps in 2024, then soared 2566 bps in 2025.
- Scholar Rock Holding's Return on Capital Employed stood at 39.77% in 2022, then plunged by 74 bps to 69.04% in 2023, then slumped by 30 bps to 89.99% in 2024, then fell by 21 bps to 109.1% in 2025, then rose by 8 bps to 99.87% in 2026.
- Business Quant data shows SRRK's Return on Capital Employed at 99.87% in Q1 2026, 109.1% in Q4 2025, and 115.35% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | -88.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -88.89% |
| Mar 31, 2026 | -99.87% |
| Dec 31, 2025 | -109.10% |
| Sep 30, 2025 | -115.35% |
| Jun 30, 2025 | -99.99% |
| Mar 31, 2025 | -67.07% |
| Dec 31, 2024 | -89.99% |
| Sep 30, 2024 | -141.01% |
| Jun 30, 2024 | -97.91% |
| Mar 31, 2024 | -75.18% |
| Dec 31, 2023 | -69.04% |
| Sep 30, 2023 | -67.90% |
| Jun 30, 2023 | -59.48% |
| Mar 31, 2023 | -54.13% |
| Dec 31, 2022 | -39.77% |
| Sep 30, 2022 | -34.62% |
| Jun 30, 2022 | -40.19% |
| Mar 31, 2022 | -43.54% |
| Dec 31, 2021 | -54.79% |
| Sep 30, 2021 | -48.15% |